WHO ICTRP trial
Pirfenidine in SARS-COV2
IRCT20200314046764N1 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20200314046764N1 |
|---|---|
| Public title | Pirfenidine in SARS-COV2 |
| Scientific title | The evaluation of pirfenidone effects on prevention and treatment of pulmonary fibrosis and acute respiratory distress syndrome caused by COVID-19 |
| Primary sponsor | Kermanshah University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Pulmonary fibrosis and acute respiratory distress syndrome caused by novel corona-virus pneumonia (COVID-19). Coronavirus infection, unspecified;B34.2 |
| Interventions | Intervention 1: Intervention group: Pirfenidone 200 mg ,three times daily in addition to standard treatment (according to the national protocol) containing Coltra Lupinavir / Ritonavir twice daily, Chloroquine 250 mg twice daily, and… |
| Registration date | Apr 20, 2020 |
| Target size | 40 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: